Study of drug PB2452 in Ticagrelor-Treated Patients with Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure
Enrolling By Invitation
18 years - 99 years
All
Phase
3
5 participants needed
1 Location
Brief description of study
The research study is being conducted to test the study drug PB2452 to see if it is safe and will reverse the bleeding effects of Brilinta® (also known as ticagrelor). Candidates must be taking Brilinta® (ticagrelor) or show intake within the past 3 days. They will be considered for participation in the study if they are experiencing uncontrolled or life-threatening bleeding or require urgent surgery where reversal of the antiplatelet effects of the medication Brilinta® (ticagrelor) is required.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Bleeding
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 850729
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
